Federal Agency Session: Special Addresses and Open Discussion
-
Register
- Non-Member - Free!
- Regular Member - Free!
- Retired - Free!
- Early Career Physician - Free!
- Resident - Free!
- Student - Free!
- Associate - Free!
- ASAM Staff - Free!
- International Member - Free!
- Emeritus Member - Free!
- Provisional Member - Free!
- Fellow Member - Free!
- Honorary Member - Free!
- CRT Member - Free!
Federal Agency Session: Special Addresses and Open Discussion
Recorded: Thursday, September 29, 2022 - Saturday, October 1, 2022
On-Demand Session
Overview
This 1-hour, on-demand session from the 2022 ASAM State of the Art Course overviews emerging issues and advances in addiction medicine at SAMHSA, NIDA, and NIAAA.
During this 1-hour, on-demand session from the 2022 ASAM State of the Art Course, federal agency leaders from SAMHSA, NIDA, and NIAAA give brief overviews about emerging issues and advances in addiction medicine from their respective organizations. Following the presentations, State of the Art Planning Committee Chair, Dr. Michael I. Fingerhood leads the agencies in a lively discussion about the most pressing topics in addiction medicine.
These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:
- Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
- Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
- Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine
This conference addresses all 6 ACGME Competencies.
Learning Objectives
At the end of the course, learners should be able to:
- Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
- Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
- Develop practical applications for integrating new and emerging science into practice.
- Identify gaps in the field of addiction medicine that future research can address.
- Create a network of colleagues and resources to support the learner's practice or form future research collaborations.
Registration Rates
| ASAM Learner Type | Rate |
| ASAM Member | $0 |
| Non-Member | $0 |
| Associate Member | $0 |
| Resident Member* | $0 |
| Student Member* | $0 |
*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Membership Question? Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.
Refunds & Cancellations
All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Registration Deadline: 10/1/2025
Instructions
- Click on the Contents tab to begin this activity.
- Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 2 out of 3 questions correctly.
- Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org
ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
.jpg "Speaker image")
Michael Fingerhood, MD FACP DFASAM (Moderator)
Associate Professor of Medicine and Public Health
Johns Hopkins University
Dr. Michael Fingerhood is an Associate Professor of Medicine and Public Health at the Johns Hopkins University. He is the Chief of the Division of Chemical Dependence and medical director of the Comprehensive Care Practice (CCP) at Johns Hopkins Bayview Medical Center. The CCP integrates substance use disorder treatment with primary medical care, including care for HIV and hepatitis C.
No Relevant Financial Disclosures
Miriam Delphin-Rittmon, PhD
Dr. Miriam E. Delphin-Rittmon is currently Assistant Secretary for Mental Health and Substance Use in the U.S. Department of Health and Human Services and the Administrator of the Substance Abuse and Mental Health Services Administration. She previously served as Commissioner of the Connecticut Department of Mental Health and Addiction Services (DMHAS) and served in this role for six years. Prior positions held at DMHAS include Deputy Commissioner, Senior Policy Advisor and Director of the department’s Office of Multicultural Healthcare Equity. In her role as Commissioner, Dr. Delphin-Rittmon was committed to promoting recovery oriented, integrated, and culturally responsive services and systems that foster dignity, respect, and meaningful community inclusion.
Prior to her current appointment, Dr. Delphin-Rittmon was an Adjunct Associate Professor at Yale University where she served on faculty for the past 20 years. While at Yale Dr. Delphin-Rittmon served as the Director of Cultural Competence and Research Consultation with the Yale University Program for Recovery and Community Health.
In May 2014, Dr. Delphin-Rittmon completed a two-year White House appointment working as a Senior Advisor to the Administrator of the Substance Abuse and Mental Health Services Administration (SAMHSA) with the U.S. Department of Health and Human Services. While at SAMHSA, she worked on a range of policy initiatives addressing behavioral health equity, workforce development, and healthcare reform.
Through her 20 year career in the behavioral health field Dr. Delphin-Rittmon has extensive experience in the design, evaluation, and administration of mental health, substance use and prevention services and systems and has received several awards for advancing policy in these areas. Most recently, she received the 2019 State Service Award from the National Association of State Drug and Alcohol Directors and the 2016 Mental Health Award for Excellence from the United Nations Committee on Mental Health.
She received her B.A. in Social Science from Hofstra University in 1989, her M.S. and Ph.D. in Clinical Psychology from Purdue University 1992 and 2001, respectively, and completed a postdoctoral fellowship in clinical community psychology at Yale University in 2002
No Relevant Financial Disclosures
Wilson Compton
MD, MPE
Wilson M. Compton, MD, MPE serves as the Deputy Director of the National Institute on Drug Abuse (NIDA) of the National Institutes of Health. In his current role, Dr. Compton's responsibilities include providing scientific leadership in the development, implementation, and management of NIDA's research portfolio and working with the Director to support and conduct research to improve the prevention and treatment of drug abuse and addiction. Prior to his current appointment, Dr. Compton served as the Director of NIDA's Division of Epidemiology, Services and Prevention Research from 2002 until 2013. In this leadership role, he oversaw the scientific direction of a complex public health research program of national and international scope addressing: 1) the extent and spread of drug abuse, 2) how to prevention drug abuse, and 3) how to implement drug abuse prevention and treatment services as effectively as possible. Before joining NIDA, Dr. Compton was Associate Professor of Psychiatry and Director of the Master in Psychiatric Epidemiology Program at Washington University in Saint Louis as well as Medical Director of Addiction Services at the Barnes-Jewish Hospital in Saint Louis. Dr. Compton received his undergraduate education from Amherst College. He attended medical school and completed his residency training in psychiatry at Washington University. During his career, Dr. Compton has achieved multiple scientific accomplishments: he was selected to serve as a member of the DSM-5 Revision Task Force; is the author of more than 130 articles and chapters; and is an invited speaker at multiple high-impact venues. Dr. Compton is the recipient of multiple awards and in 2008, he received the Senior Scholar Health Services Research Award from the American Psychiatric Association, in 2010 the Paul Hoch Award from the American Psychopathological Association, in both 2012 and 2013, he was selected to receive the Leveraging Collaboration Award from the Food and Drug Administration. In 2013, Dr. Compton received the prestigious Health and Human Services Secretary's Award for Meritorious Service.
Does Disclose: 3M Companies: Ownership Interest includes stock, stock options, patent or other intellectual property; General Electric Co.: Ownership Interest includes stock, stock options, patent or other intellectual property Pfizer, Inc.: Ownership Interest includes stock, stock options, patent or other intellectual property.
Aaron White, PhD
Leader, Epidemiology and Biometry Branch and Senior Scientific Advisor to the Director
National Institute on Alcohol Abuse and Alcoholism
Aaron White is the Senior Scientific Advisor to the Director at the National Institute on Alcohol Abuse and Alcoholism (NIAAA). His areas of scientific expertise include the brain mechanisms and epidemiology of alcohol-induced memory blackouts, and the impact of alcohol and other drugs on brain function and behavior, particularly during the adolescent years.
Dr. White co-wrote the online alcohol prevention course, AlcoholEdu, which has been completed by more than 3 million high school and college students to date. He joined NIAAA in 2008 and, until recently, was a Program Officer in the Division of Epidemiology and Prevention Research. As a Program Officer, Dr. White oversaw a large portfolio of grants covering epidemiology and prevention research related to underage and college drinking. In 2015, he was promoted to Senior Scientific Advisor to the Director, Dr. George Koob. In this position, Dr. White advises the Director regarding a wide variety of scientific topic areas in alcohol and other drug research.
He also frequently takes part in media interviews and delivers presentations on behalf of the Institute, including presentations on addiction and overdoses at a meeting of the United Nations Office of Drugs and Crime in Austria last fall. He is an author on 37 peer-reviewed manuscripts, 22 review papers and book chapters, 3 books and has delivered several hundred presentations about alcohol and the brain.
No Relevant Financial Disclosures
CME, CE, CEU and Other Credit Types
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
NAADAC, the Association for Addiction Professionals
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1222
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1222
Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.
Maintenance of Certification (MOC) / Continuing Certification Program (CCP)
The ASAM State of the Art Course meets the CME requirements for the following primary boards:
• American Board of Medical Specialties (ABMS)
• American Board of Preventive Medicine (ABPM)
• American Board of Anesthesiology (ABA)
• American Board of Pediatrics (ABP)
• American Board of Internal Medicine (ABIM)
• American Board of Surgery (ABS)
• American Board of Psychiatry and Neurology (ABPN)
• American Board of Addiction Medicine (ABAM)
• Royal College of Physicians and Surgeons of Canada (RCPSC
Disclosure Information
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
Key:
Complete
Next
Failed
Available
Locked